{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hepatitis-a/prescribing-information/hepatitis-a-vaccine/","result":{"pageContext":{"chapter":{"id":"7d022e5d-ab4e-50bf-b90f-5611cf3a17db","slug":"hepatitis-a-vaccine","fullItemName":"Hepatitis A vaccine","depth":2,"htmlHeader":"<!-- begin field e4f073c7-827e-4bcb-a183-37eeb34e878e --><h2>What issues should I consider before giving hepatitis A vaccine?</h2><!-- end field e4f073c7-827e-4bcb-a183-37eeb34e878e -->","summary":"","htmlStringContent":"<!-- begin item 5aeeaec4-b3ed-4113-ad13-ed4238074c62 --><!-- end item 5aeeaec4-b3ed-4113-ad13-ed4238074c62 -->","topic":{"id":"29ac65ab-afdd-58a1-bb07-9c101977d24d","topicId":"580cfa7a-647b-439a-8f8c-493cb6bd4332","topicName":"Hepatitis A","slug":"hepatitis-a","lastRevised":"Last revised in January 2021","chapters":[{"id":"d47cd8cf-fe05-5aa4-997b-01a20519d12f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bbe6550-f4f5-5279-9e9e-04b38f9dc672","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"75791cbd-6d69-555e-83e8-9ac8cca25c50","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c0ae1a2d-febe-5ec7-821a-0616062456ee","slug":"changes","fullItemName":"Changes"},{"id":"434eb73d-f60d-5f1f-ba10-5aa77d904da1","slug":"update","fullItemName":"Update"}]},{"id":"242c9e8c-5867-5598-9168-62160e8ae293","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"6c2f4656-f9e8-56be-aa43-3f6a9aa45aa8","slug":"goals","fullItemName":"Goals"},{"id":"71c0a726-22c7-568b-b925-d10cc97ace3a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"70e8a1cd-fd5b-50d7-8ce4-b6f29981218d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"37bb7a58-62c9-52be-b97c-7b99f8317f12","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"badbd40f-9ce6-5f8a-9f65-8be03bc8d3fe","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ed9f7297-1f33-5365-8e4f-3844542af45d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6a11034-e31c-5039-8ca7-b463c00b2039","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a2206363-5f44-5348-b469-07b49a6a9647","slug":"definition","fullItemName":"Definition"},{"id":"dd1ca873-1bf9-500d-a574-fc92c8589e62","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bdd89354-2f0b-564c-b589-cb043e32b99c","slug":"transmission","fullItemName":"Transmission"},{"id":"8e72bb81-12fd-5a0e-976b-d18d62788974","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ab3f5823-00db-5e27-a434-c323c357ab02","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"e879b74c-3d75-59c5-806e-4b39a6e72901","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"94f8b729-5e94-57ee-b96e-ca1561614640","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"6b32fed7-c15e-5976-adc6-692994cbab9e","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"2503640c-54cf-53e1-b29c-fc9c19cbd52a","slug":"investigations","fullItemName":"Investigations"},{"id":"88a35298-3760-53b6-b4ff-b9e0677b4df3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9ba7b244-14ec-5fd1-9b2b-151b9c48bfab","fullItemName":"Management","slug":"management","subChapters":[{"id":"1a3874e3-8562-5ca6-8c97-4d9a2a009e75","slug":"prevention-of-infection-with-hepatitis-a","fullItemName":"Scenario: Prevention of infection with hepatitis A"},{"id":"49c1d671-61dd-5a60-974f-069b03d80d11","slug":"managing-hepatitis-a-infection","fullItemName":"Scenario: Managing hepatitis A infection"},{"id":"449ffa79-3397-54a1-a4d5-0efa55ee889f","slug":"contact-with-hepatitis-a","fullItemName":"Scenario: Contact with hepatitis A"}]},{"id":"8ffd203a-96db-5a38-a7bd-0186b97b6600","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"7d022e5d-ab4e-50bf-b90f-5611cf3a17db","slug":"hepatitis-a-vaccine","fullItemName":"Hepatitis A vaccine"},{"id":"7d0e86fd-3666-5a09-b539-4497227285ee","slug":"analgesia","fullItemName":"Analgesia"},{"id":"0ee2b156-78a9-52f6-ab80-fff22c46ff66","slug":"anti-emetics","fullItemName":"Anti-emetics"},{"id":"508e578c-aa68-5cdb-aa90-ef8889919c08","slug":"anti-pruritics","fullItemName":"Anti-pruritics"}]},{"id":"bf6b787f-fbb7-5d8d-bd85-cfe063c76fcd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e0bba353-de5a-55b9-9171-a677ecc4b97a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2571e87f-4ad0-5f6d-8c0e-8c9c86054278","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"94bd9363-8cd1-5ba6-8fd3-11f5a3ce29dd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2db0f1a2-7d4b-5fd2-a8bf-db32553e5b89","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"29233885-dedb-5c3b-ba7e-1aae299ecfe2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0a3a365f-c89a-5f1e-8ce5-1078ade19779","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1afe9613-76a4-50b9-8941-c2a2ebec23cc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"8ffd203a-96db-5a38-a7bd-0186b97b6600","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"713a3603-d077-5f3b-bcfc-705ee8e12f24","slug":"types-of-vaccine","fullItemName":"Types of vaccine","depth":3,"htmlHeader":"<!-- begin field 33a2776a-ffad-49b0-a88e-b4fef656b575 --><h3>What types of hepatitis A vaccine are available?</h3><!-- end field 33a2776a-ffad-49b0-a88e-b4fef656b575 -->","summary":"","htmlStringContent":"<!-- begin item f8c542ba-71ce-41e4-964a-451f99b7dd03 --><!-- begin field ff8e5acf-855e-4035-b646-ee6632074b40 --><ul><li>There are several hepatitis A vaccines that are licensed for use in the UK. All are inactivated, and prepared from different strains of the hepatitis A virus:<ul><li>Avaxim<sup>®</sup></li><li>Havrix Monodose<sup>®</sup></li><li>Havrix Junior Monodose<sup>®</sup></li><li>Vaqta<sup>®</sup></li><li>Vaqta Paediatric<sup>®</sup></li></ul></li><li>There are also combined hepatitis A and B vaccines:<ul><li>Twinrix<sup>® </sup>(adult and paediatric formulations)</li><li>Ambirix<sup>® </sup>(paediatric formulation)</li></ul></li><li>A combined hepatitis A and typhoid vaccine (ViATIM<sup>®</sup>) is also available.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">PHE, 2013b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">NaTHNaC, 2019</a>]</p><!-- end field ff8e5acf-855e-4035-b646-ee6632074b40 --><!-- end item f8c542ba-71ce-41e4-964a-451f99b7dd03 -->","subChapters":[]},{"id":"e2f12529-69a3-5074-b143-8b0ac43541db","slug":"immunization-schedule","fullItemName":"Immunization schedule","depth":3,"htmlHeader":"<!-- begin field f0e9d97d-1f1d-42e1-9562-93e2b7521489 --><h3>What is the immunization schedule for the hepatitis A vaccine?</h3><!-- end field f0e9d97d-1f1d-42e1-9562-93e2b7521489 -->","summary":"","htmlStringContent":"<!-- begin item 35b8c4d2-02a5-4eb0-8b98-c41ff4b83306 --><!-- begin field 2521ea4a-5433-45f8-8305-f31964890e80 --><ul><li><strong>The hepatitis A monovalent vaccine </strong>is given as two doses, 6–12 months apart.<ul><li>If the second dose has been missed there is no need to restart immunization. Give the second dose as soon as possible after the missed dose.</li><li>Antibodies may not be detectable for 12–15 days following administration of monovalent hepatitis A vaccine. However, the vaccine may provide some protection before antibodies can be detected, and vaccination up to the day of departure may be beneficial.</li><li>Immunity theoretically persists for more than 20 years after the second dose. A further booster dose is recommended at 25 years for people at ongoing risk of infection.</li></ul></li><li><strong>The schedule for the combined hepatitis A and B vaccine </strong>varies between products:<ul><li>Twinrix<sup>® </sup>is given as three doses, at 0, 1, and 6 months.<ul><li>If Twinrix<sup>® </sup>is given as a rapid schedule (on days 0, 7, and 21), a booster dose is needed at 1 year.</li></ul></li><li>Ambirix<sup>® </sup>is given as two doses, 6–12 months apart.</li></ul></li><li>For travellers, the first dose of hepatitis A single or combined vaccine should ideally be given at least 2 weeks before travelling (but can be given up to the day of departure).</li><li>Havrix Monodose<sup>®</sup> can be given concomitantly with monovalent and combination vaccines comprised of measles, mumps, rubella and varicella. When concomitant administration is considered necessary the vaccines must be given at different injection sites. Havrix Monodose<sup>®</sup> must not be mixed with other vaccines in the same syringe [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">ABPI Medicines Compendium, 2016</a>].</li><li><strong>Note: In 2017, Public Health England released temporary recommendations in response to a global shortage of monovalent hepatitis A vaccine</strong>, in order to preserve adult monovalent vaccine stocks for groups most likely to benefit. Please consult PHE's <a data-hyperlink-id=\"14d277d7-1392-4320-93c3-aafe015a2fc5\" href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/625741/Hepatitis_A_vaccination_recommendations.pdf\">guidance</a> where vaccine supply issues have been noted.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">PHE, 2013b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">NaTHNaC, 2019</a>]</p><!-- end field 2521ea4a-5433-45f8-8305-f31964890e80 --><!-- end item 35b8c4d2-02a5-4eb0-8b98-c41ff4b83306 -->","subChapters":[]},{"id":"4a8aba4d-9baa-5ef9-a54e-0590c1bccb44","slug":"people-with-hiv","fullItemName":"People with HIV","depth":3,"htmlHeader":"<!-- begin field 6a4ebaf5-a730-4da1-9130-fd4dfea9eb87 --><h3>What hepatitis A vaccination schedule should be used for people with HIV?</h3><!-- end field 6a4ebaf5-a730-4da1-9130-fd4dfea9eb87 -->","summary":"","htmlStringContent":"<!-- begin item 8b98c487-61d5-4a92-bff0-d37881112c0a --><!-- begin field f6216693-c250-40c0-81de-b8c0788b0da9 --><ul><li><strong>People with HIV and who are immunocompromised can be given hepatitis A vaccines, but they may have a poorer immune response than immunocompetent people, related to their CD4 count at the time of immunization.</strong></li><li><strong>For people who are HIV positive receiving a monovalent hepatitis A vaccine:</strong><ul><li>Those with CD4 cell counts >350 cells/μL should be offered two vaccine doses at 0 and 6 months.</li><li>Those with CD4 cell counts <350 cells/μL should receive three vaccine doses at 0, 1, and 6 months in order to increase antibody levels and longevity, especially if they are likely to be at continued risk of exposure.</li><li>If those with a low CD4 count (<300 cells/μL) exhibit negative <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-a/diagnosis/investigations/\">HAV IgG</a> following vaccination, they should be revaccinated if their CD4 count rises above 500/mm3 as a result of effective HIV treatment.</li><li>People at ongoing risk of infection should be given a booster dose of hepatitis A vaccine every 10 years.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">PHE, 2013b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">BHIVA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">BASHH, 2017</a>] </p><!-- end field f6216693-c250-40c0-81de-b8c0788b0da9 --><!-- end item 8b98c487-61d5-4a92-bff0-d37881112c0a -->","subChapters":[]},{"id":"02017d09-2fd9-5fd9-8dff-472359e4b661","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field b23591cf-b680-478c-97eb-17b7735bb4d3 --><h3>When is the hepatitis A vaccine contraindicated?</h3><!-- end field b23591cf-b680-478c-97eb-17b7735bb4d3 -->","summary":"","htmlStringContent":"<!-- begin item 71d2caff-37f5-4c1c-ae2e-da2b02a36670 --><!-- begin field b517b2f3-482d-4a9d-b38a-25828e40b80e --><ul><li>Do not give hepatitis A vaccine if the person has:<ul><li>A current severe febrile illness.</li><li>Experienced a confirmed anaphylactic reaction to a previous dose of hepatitis A vaccine, or to any component of the vaccine.<ul><li>Epaxal<sup>® </sup>should not be given to people who have had a confirmed anaphylactic reaction to egg.</li><li>Avaxim<sup>®</sup>, Twinrix<sup>®</sup>, and Ambirix<sup>® </sup>should not be given to people who have had a confirmed anaphylactic reaction to neomycin.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">PHE, 2013b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">ABPI Medicines Compendium, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">ABPI, 2019a</a>] </p><!-- end field b517b2f3-482d-4a9d-b38a-25828e40b80e --><!-- end item 71d2caff-37f5-4c1c-ae2e-da2b02a36670 -->","subChapters":[]},{"id":"86f9f4c2-b215-58f3-b749-88f5085241f0","slug":"administration","fullItemName":"Administration","depth":3,"htmlHeader":"<!-- begin field 243c5c30-07cd-4af3-a797-ebe14e504ac2 --><h3>How should I administer the hepatitis A vaccine?</h3><!-- end field 243c5c30-07cd-4af3-a797-ebe14e504ac2 -->","summary":"","htmlStringContent":"<!-- begin item 06df4219-0fe0-40a5-a844-671fb17648a5 --><!-- begin field 2d923999-c474-48dc-849e-d4bbe07ca03b --><ul><li>Obtain written or verbal consent at the time of vaccination.</li><li>Check that the vaccine is correct and has not expired. Only clean the site of application with soap and water if it is visibly dirty.</li><li>For adults and children older than 1 year of age, administer the vaccine by intramuscular injection into the deltoid muscle or the anterolateral aspect of the thigh.</li><li>For children younger than 1 year of age, administer the vaccine by intramuscular injection into the anterolateral aspect of the thigh.</li><li>If the person has a bleeding disorder, use the deep subcutaneous route, to reduce the risk of bleeding.</li><li>Record the site of administration. If an additional vaccine is required on the same day, use separate limbs if possible, or inject at sites at least 2.5 cm apart in the same limb.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">PHE, 2013c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">PHE, 2013d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">PHE, 2013b</a>]</p><!-- end field 2d923999-c474-48dc-849e-d4bbe07ca03b --><!-- end item 06df4219-0fe0-40a5-a844-671fb17648a5 -->","subChapters":[]},{"id":"3edfcfe0-579a-596c-ae1b-d9c79807ba1f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 778508e8-c3f4-45d7-afdc-f08bb9acf01e --><h3>What are the adverse effects of the hepatitis A vaccine?</h3><!-- end field 778508e8-c3f4-45d7-afdc-f08bb9acf01e -->","summary":"","htmlStringContent":"<!-- begin item de2458d2-8be6-4bf6-bb6a-ac388805742f --><!-- begin field f474086b-40f9-4bd5-8496-f949a8e276cb --><ul><li>Adverse effects of hepatitis A vaccines are usually mild and only occur within the first few days following immunization. The most common reactions are mild, transient soreness, and erythema. Induration or a small, painless nodule may form at the injection site — this usually disappears and is of no consequence.</li><li>General symptoms (such as fever, malaise, fatigue, headache, nausea, and loss of appetite) are also reported less frequently.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">PHE, 2013b</a>]</p><!-- end field f474086b-40f9-4bd5-8496-f949a8e276cb --><!-- end item de2458d2-8be6-4bf6-bb6a-ac388805742f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}